Transition to a Pure Holding Company Structure Suited to a Diversified Group
First written in FY2021. 3 of 7 entries say "Restated". Latest entry: 2026-05-27.
13 other companies' latest entry also says "Advanced".
- 2026-05-27AdvancedM&A and Subsidiary Changes
「Through this merger, we will integrate the operations and management resources of both companies to improve the efficiency of the group's management structure and reduce operating and administrative costs, thereby contributing to higher corporate value over the medium to long term.」
The company resolved that 医化学創薬 would absorb プライミューン and MASC would absorb メディフォム, with the mergers scheduled for 1 October 2026, thereby putting into concrete form the integration of group operations and management resources and improvements in administrative efficiency. - FY2025-H1AdvancedAnnual report
「The Company had been preparing to integrate the management of the core companies 新薬リサーチセンター and 安評センター for the purpose of further streamlining business operations through the consolidation of management resources and strengthening competitiveness and sales capabilities. The companies merged as scheduled on 1 October 2024.」
As part of the group restructuring following the transition to a pure holding company structure, the merger of 新薬リサーチセンター and 安評センター was completed as scheduled on 1 October 2024, advancing the next stage of integration. - FY2024-Q3AdvancedAnnual report
「In November 2023, the Company resolved to integrate the management of 新薬リサーチセンター and 安評センター through a merger scheduled for 1 October 2024, with the aim of further streamlining business operations by consolidating management resources, strengthening sales capabilities and establishing a core company with strong competitiveness as the final stage of the group restructuring.」
As the next stage of the group restructuring following the transition to a pure holding company structure, the Company resolved to integrate the management of 新薬リサーチセンター and 安評センター through a merger scheduled for 1 October 2024. - FY2022-Q3RestatedAnnual report
「For the purpose of improving management efficiency and strengthening the functions of the drug discovery support business, on 1 April 2021 the Company transferred its genetically modified mouse business to its subsidiary 株式会社安評センター and its antibody business to its subsidiary 医化学創薬株式会社, respectively, and transitioned to a pure holding company structure with a group governance framework suited to a diversified group.」
The Company reconfirmed that the transfer of the genetically modified mouse and antibody businesses and the transition to a pure holding company structure were measures to improve efficiency and strengthen functions in the drug discovery support business and establish governance for a diversified group. - FY2022-Q2RestatedAnnual report
「For the purpose of improving management efficiency and strengthening the functions of the drug discovery support business, on 1 April 2021 the Company transferred its genetically modified mouse business to its subsidiary 株式会社安評センター and its antibody business to its subsidiary 医化学創薬株式会社, respectively, and transitioned to a pure holding company structure with a group governance framework suited to a diversified group.」
The Company reconfirmed that the genetically modified mouse business and antibody business were transferred to subsidiaries and that the Company transitioned to a pure holding company structure, as measures to improve management efficiency and strengthen the functions of the drug discovery support business and establish a governance framework suited to a diversified group. - FY2022-Q1RestatedAnnual report
「For the purpose of improving management efficiency and strengthening the functions of the drug discovery support business, on 1 April 2021 the Company transferred its genetically modified mouse business to its subsidiary 株式会社安評センター and its antibody business to its subsidiary 医化学創薬株式会社, respectively, and transitioned to a pure holding company structure with a group governance framework suited to a diversified group.」
The Company reconfirmed that the business transfers and transition to a pure holding company structure were completed on 1 April 2021, and that their objectives were to improve management efficiency and strengthen the functions of the drug discovery support business, as well as establish a governance framework suited to a diversified group. - FY2021First statedAnnual report
「The Company completed the transfer of the relevant business and the transition to a pure holding company on 1 April 2021. By transitioning to a pure holding company structure suited to the governance of a diversified group, the Company sought to optimize the allocation of management resources, establish optimal operating structures suited to the characteristics of each business, and improve agility.」
In response to the increase in group companies and expansion in business scale, the transition to a pure holding company structure was completed on 1 April 2021. The objective was to optimize the allocation of management resources, business operations and governance in line with the diversified group.